{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:37:45Z","timestamp":1761622665237,"version":"build-2065373602"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Health-related quality of life (HRQoL) remains underassessed and underreporting in randomized clinical trials (RCTs) evaluating new therapies in metastatic non-small cell lung cancer (NSCLC). However, evaluation and preservation of favorable HRQoL are critically important in trials including patients in early-stage settings, in which the primary objective is cure. Herein, we evaluated whether HRQoL was adequately evaluated and reported in trials including immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in resectable NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was performed on Embase and PubMed to identify RCTs testing TKIs or ICIs in resectable NSCLC. We selected full articles and abstracts from major meetings. Risk of bias and reporting assessment of HRQoL were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of October 2024, we identified 25 RCTs. The primary endpoint was overall survival for 2 RCTs, while 21 and 7 RCTs evaluated risk of recurrence and tumour response as (co)-primary endpoints, respectively. Twelve RCTs (48%) did not assess HRQoL as an endpoint, while 13 (52%) included HRQoL evaluation as a secondary or exploratory endpoint. The most common tools utilized were FACT-L (6\/13; 46%), EORTC-QLQ30\/LC13 (4\/13; 30%) and SF-36 (2\/13; 15%). Phase II (33%) and adjuvant (44%) trials evaluated HRQoL in a lower rate than phase III (62%) and neoadjuvant\/perioperative (66%) RCTs. Three out of 22 RCTs (14%) with available full-texts reported HRQoL results in the primary publication. Two out of the 19 remaining RCTs reported HRQoL in an indipendent publications, and 2 of them presented data in meeting abstracts. Remarkably, for 15 (68%) RCTs HRQoL evaluation is not available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our systematic evaluation revealed suboptimal evaluation and underreporting of HRQoL in patients treated with novel agents and combinations in resectable NSCLC. Systematic evaluation and reporting of HRQoL should be prioritized in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf339","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:00:00Z","timestamp":1759492800000},"source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-1803","authenticated-orcid":false,"given":"Fabio","family":"Salomone","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Novero","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-0508","authenticated-orcid":false,"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[{"name":"Bocconi School of Management, Center for Research on Health and Social Care Management , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3571-7006","authenticated-orcid":false,"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]},{"name":"Universit\u00e0 Vita-Salute San Raffaele , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3624-224X","authenticated-orcid":false,"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narjust","family":"Florez","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan , Milan,","place":["Italy"]},{"name":"Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS , Milan,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-5441","authenticated-orcid":false,"given":"Cecilia","family":"Pompili","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Institute for Clinical & Applied Health Research, University of Hull , Hull,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025102723312166300_oyaf339-B1","article-title":"Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality","volume":"2022","author":"Bonney","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025102723312166300_oyaf339-B2","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.21037\/jtd.2020.02.46","article-title":"Novel treatment strategies for early-stage lung cancer: the oncologist\u2019s perspective","volume":"12","author":"Indini","year":"2020","journal-title":"J Thorac Dis."},{"key":"2025102723312166300_oyaf339-B3","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.21037\/jtd.2019.04.91","article-title":"Long-term impact of complications after lung resections in non-small cell lung cancer","volume":"11","author":"Shinohara","year":"2019","journal-title":"J Thorac Dis."},{"key":"2025102723312166300_oyaf339-B4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/oncolo\/oyac140","article-title":"Clinical features, survival, and burden of toxicities in survivors more than one year after lung cancer immunotherapy","volume":"27","author":"Hsu","year":"2022","journal-title":"Oncologist."},{"key":"2025102723312166300_oyaf339-B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2019.03.009","article-title":"Understanding patients\u2019 values and preferences regarding early stage lung cancer treatment decision making","volume":"131","author":"Sullivan","year":"2019","journal-title":"Lung Cancer"},{"key":"2025102723312166300_oyaf339-B6","doi-asserted-by":"crossref","first-page":"101119","DOI":"10.1016\/j.imr.2024.101119","article-title":"Patient-focused drug development and real-world study","volume":"14","author":"Hu","year":"2025","journal-title":"Integr Med Res."},{"key":"2025102723312166300_oyaf339-B7","doi-asserted-by":"crossref","first-page":"622154","DOI":"10.3389\/fpubh.2021.622154","article-title":"Patient preferences for lung cancer treatment: a qualitative study protocol among advanced lung cancer patients","volume":"9","author":"Durosini","year":"2021","journal-title":"Front Public Health."},{"key":"2025102723312166300_oyaf339-B8","doi-asserted-by":"crossref","first-page":"602112","DOI":"10.3389\/fphar.2021.602112","article-title":"What matters most to lung cancer patients? A qualitative study in Italy and Belgium to investigate patient preferences","volume":"12","author":"Petrocchi","year":"2021","journal-title":"Front Pharmacol."},{"key":"2025102723312166300_oyaf339-B9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"2025102723312166300_oyaf339-B10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/ejcts\/ezs532","article-title":"Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer","volume":"43","author":"Pompili","year":"2013","journal-title":"Eur J Cardiothorac Surg."},{"key":"2025102723312166300_oyaf339-B11","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/annonc\/12.suppl_3.S7","article-title":"Health-related quality of life measures in cancer","volume":"12 Suppl 3","author":"Tamburini","year":"2001","journal-title":"Ann Oncol"},{"key":"2025102723312166300_oyaf339-B12","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3389\/fpsyg.2019.02147","article-title":"Dimensionality and measurement invariance of the italian version of the EORTC QLQ-C30 in postoperative lung cancer patients","volume":"10","author":"Marzorati","year":"2019","journal-title":"Front Psychol."},{"key":"2025102723312166300_oyaf339-B13","doi-asserted-by":"crossref","first-page":"114161","DOI":"10.1016\/j.ejca.2024.114161","article-title":"The development of an archive of patient-reported outcome measures (PROMs) in oncology: the Italian PRO4All project","volume":"207","author":"Malandrini","year":"2024","journal-title":"Eur J Cancer."},{"key":"2025102723312166300_oyaf339-B14","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/bmjonc-2022-000021","article-title":"Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study","volume":"2","author":"Marandino","year":"2023","journal-title":"BMJ Oncol."},{"key":"2025102723312166300_oyaf339-B15","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.jtho.2024.09.207","article-title":"MA14.13 analysis of lung cancer-specific patient-reported outcome measures (PROMs): results from the PRO4All project","volume":"19","author":"Servetto","year":"2024","journal-title":"J Thoracic Oncol"},{"key":"2025102723312166300_oyaf339-B16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2022.10.003","article-title":"Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC","volume":"174","author":"Salomone","year":"2022","journal-title":"Lung Cancer."},{"key":"2025102723312166300_oyaf339-B17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ejcts\/ezw363","article-title":"Poor preoperative patient-reported quality of life is associated with complications following pulmonary lobectomy for lung cancer","volume":"51","author":"Pompili","year":"2017","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"2025102723312166300_oyaf339-B18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14338\/IJPT-19-00072.1","article-title":"Survivor and caregiver expectations and preferences regarding lung cancer treatment","volume":"6","author":"Wieland","year":"2019","journal-title":"Int J Part Ther."},{"key":"2025102723312166300_oyaf339-B19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.athoracsur.2022.09.047","article-title":"Patient-reported physical function is associated with survival after lung resection for non-small cell lung cancer","volume":"116","author":"Pompili","year":"2023","journal-title":"Ann Thorac Surg."},{"key":"2025102723312166300_oyaf339-B20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/03007995.2025.2456009","article-title":"Patient and caregiver insights into lung cancer treatment decision-making: an exploratory focus group","volume":"41","author":"Vanderpoel","year":"2025","journal-title":"Curr Med Res Opin."},{"key":"2025102723312166300_oyaf339-B21","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg."},{"key":"2025102723312166300_oyaf339-B22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025102723312166300_oyaf339-B23"},{"key":"2025102723312166300_oyaf339-B24"},{"key":"2025102723312166300_oyaf339-B25","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol."},{"key":"2025102723312166300_oyaf339-B26","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","article-title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016","volume":"29","author":"Marandino","year":"2018","journal-title":"Ann Oncol."},{"key":"2025102723312166300_oyaf339-B27","doi-asserted-by":"crossref","first-page":"e000179","DOI":"10.1136\/bmjonc-2023-000179","article-title":"Endpoints for trials of adjuvant anticancer therapies","volume":"2","author":"Pastorino","year":"2023","journal-title":"BMJ Oncol."},{"key":"2025102723312166300_oyaf339-B28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol."},{"key":"2025102723312166300_oyaf339-B29","doi-asserted-by":"crossref","first-page":"e252668","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open."},{"key":"2025102723312166300_oyaf339-B30","doi-asserted-by":"crossref","first-page":"107419","DOI":"10.1016\/j.lungcan.2023.107419","article-title":"Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: a review","volume":"187","author":"Majem","year":"2024","journal-title":"Lung Cancer."},{"key":"2025102723312166300_oyaf339-B31","first-page":"38","article-title":"Choosing your partner for the PROM: a review of evidence on patient-reported outcome measures for use in primary and community care","volume":"10","author":"Bryan","year":"2014","journal-title":"Healthc Policy"},{"key":"2025102723312166300_oyaf339-B32","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med."},{"key":"2025102723312166300_oyaf339-B33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med."},{"key":"2025102723312166300_oyaf339-B34","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med."},{"key":"2025102723312166300_oyaf339-B35","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med."},{"key":"2025102723312166300_oyaf339-B36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.athoracsur.2010.05.014","article-title":"Systematic classification of morbidity and mortality after thoracic surgery","volume":"90","author":"Seely","year":"2010","journal-title":"Ann Thorac Surg."},{"key":"2025102723312166300_oyaf339-B37","doi-asserted-by":"crossref","first-page":"103654","DOI":"10.1016\/j.esmoop.2024.103654","article-title":"Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: a meta-research study of randomized phase III trials in oncology","volume":"9","author":"Paratore","year":"2024","journal-title":"ESMO Open."},{"key":"2025102723312166300_oyaf339-B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12955-025-02357-z","article-title":"Psychosocial factors associated with quality of life in cancer patients undergoing treatment: an umbrella review","volume":"23","author":"Marzorati","year":"2025","journal-title":"Health Qual Life Outcomes."},{"key":"2025102723312166300_oyaf339-B39","doi-asserted-by":"crossref","first-page":"1087083","DOI":"10.3389\/fpsyg.2023.1087083","article-title":"Patients\u2019 representation of oncological disease: psychological aspects in the cancer journey","volume":"14","author":"Durosini","year":"2023","journal-title":"Front Psychol."},{"key":"2025102723312166300_oyaf339-B40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.clinthera.2018.04.003","article-title":"Safety versus tolerability","volume":"40","author":"Shader","year":"2018","journal-title":"Clin Ther."},{"key":"2025102723312166300_oyaf339-B41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaoncol.2014.112","article-title":"Association of actual and preferred decision roles with patient-reported quality of care","volume":"1","author":"Kehl","year":"2015","journal-title":"JAMA Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf339\/64539597\/oyaf339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf339\/64539597\/oyaf339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf339\/64539597\/oyaf339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:31:32Z","timestamp":1761622292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf339\/8277022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf339","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"article-number":"oyaf339"}}